Bausch Health Companies (BHC) Cash & Equivalents (2009 - 2026)

Bausch Health Companies (BHC) has 18 years of Cash & Equivalents data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 14.55% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 14.55% YoY), and the FY2025 full-year result was $1.3 billion, up 10.84% from the prior year.
• Cash & Equivalents eased to $1.3 billion in Q1 2026, from $1.3 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q2 2025 to a low of $486.0 million in Q3 2022.
• A 5-year average of $927.5 million and a median of $760.0 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 58.53% in 2023 and surged 190.25% in 2025, its largest moves.
• Tracing BHC's Cash & Equivalents over 5 years: stood at $564.0 million in 2022, then surged by 67.91% to $947.0 million in 2023, then climbed by 24.71% to $1.2 billion in 2024, then advanced by 10.84% to $1.3 billion in 2025, then declined by 0.76% to $1.3 billion in 2026.
• Business Quant data shows BHC's Cash & Equivalents at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.